SELLAS Life Sciences Group (SLS) AI Stock Analysis

• Market Cap: $854.81M
• Dividend Yield: N/A
• Average Volume (3M): 6.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: N/A
• EPS Growth: 59.04%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 179,582,580
• 10 Day Avg. Volume: 8,847,238
• 30 Day Avg. Volume: 6,918,579
• PEG Ratio: 0.31
• Price to Book (P/B): 5.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -14.48
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -29.43
• 1Y Price Target: $10.00
• Price Target Upside: 143.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.32
• Revenue Forecast (FY): $36.13M

• Rating: 49 Neutral
• Price Target: $4.50 ▲(9.49% Upside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is primarily held down by weak financial performance, marked by ongoing losses, zero recent revenue, and sustained negative cash flow. Technicals are modestly supportive over the longer term but lack strong near-term momentum. Corporate events improve liquidity via warrant-exercise proceeds, partially offset by dilution risk, while valuation remains constrained by negative earnings.

Positive Factors

Targeted immunotherapy pipeline

SELLAS has a focused clinical-stage pipeline (GPS, NPS) targeting validated cancer antigens (WT1, HER2). A narrow, antigen-targeted immunotherapy strategy is a durable fundamental: if clinical proofs emerge, the approach can scale across hematologic and solid tumors and sustain long-term program value.

Low financial leverage

Reported debt levels are minimal relative to equity, lowering near-term solvency and interest burden risks. Low leverage is a lasting structural strength for a pre-commercial biotech, providing flexibility to manage clinical spending and negotiate partnership or financings without heavy fixed-cost pressure.

Material cash raised via warrant exercises

The ~$42.6M of warrant-exercise proceeds materially bolsters near-term liquidity and extends runway, enabling continued clinical development without immediate debt. This structural capital infusion reduces the urgency of near-term financings and supports execution of development milestones over the coming months.

Negative Factors

No recurring revenue and persistent losses

SELLAS lacks product revenue and shows sustained operating and net losses, leaving the company dependent on external capital. This durable weakness raises funding risk, limits internal reinvestment capacity, and makes long-term program funding contingent on capital markets or partnerships.

Consistent negative operating and free cash flow

Persistent cash burn and negative FCF mean the company must repeatedly access markets for funding, creating recurring dilution risk. Negative cash flow also constrains the ability to accelerate trials or expand operations without external support, a structural limitation on growth prospects.

Equity dilution and equity volatility

Recent warrant conversions materially increased share count and equity volatility (equity swung from negative to positive), reducing per-share upside and compounding investor dilution risk. For a non‑revenue biotech, recurring equity issuance is a structural shareholder-return headwind over months.

SELLAS Life Sciences Group Business Overview & Revenue Model

Company Description

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, SELLAS has historically not been described as generating material recurring revenue from commercial product sales, and its operations have generally been funded through financing activities and other non-product sources typical for pre-commercial biotech companies. Specific, company-disclosed recurring revenue streams (e.g., product sales, royalties, or significant ongoing collaboration/service revenue) are not available in this response context and are therefore null. Material earnings drivers, to the extent applicable for such a company, would typically include (i) equity financings (public/common stock offerings, PIPEs, at-the-market programs), (ii) debt or other financing arrangements, and (iii) if and when executed, licensing or collaboration agreements that could provide upfront payments, milestone payments, cost-sharing, and/or royalties tied to development and commercialization. However, details of current or recent significant partnerships and the exact composition of reported revenues (if any) are not available here and are therefore null.

SELLAS Life Sciences Group Financial Statement Overview

Summary

Financial profile remains weak with persistent net losses (about -$26.9M in 2025) and effectively zero revenue in 2023–2025. Balance sheet leverage is low, but recurring losses and consistently negative operating/free cash flow (about -$28.4M FCF in 2025) keep funding and sustainability risk elevated despite modest improvement in burn.

Income Statement

Profitability remains weak, with persistent operating and net losses every year shown (net loss of ~$26.9M in 2025 vs. ~$30.9M in 2024, an improvement but still deeply negative). Revenue has effectively collapsed to zero in recent years (2023–2025 show $0 revenue vs. $7.6M in 2021), limiting visibility into any operating leverage. While the loss trend improved from the 2022–2023 trough, the overall earnings profile is still dominated by heavy losses and no meaningful revenue base.

Balance Sheet

Leverage appears low based on reported debt relative to equity in 2024–2025 (debt-to-equity ~0.11 in 2024 and ~0.01 in 2025), which reduces near-term balance sheet strain from borrowings. However, equity quality and stability have been volatile (equity was negative in 2023 and then rebounded sharply by 2025), and returns on equity are meaningfully negative in the latest periods due to ongoing losses. Overall, the balance sheet shows limited debt but elevated risk from recurring losses and large swings in equity.

Cash Flow

Cash generation is a key weakness: operating cash flow and free cash flow are consistently negative across all periods, including roughly -$28.4M in 2025 and -$35.4M in 2024. The cash burn improved year over year in 2025, but free cash flow growth is highly volatile and remains firmly negative in absolute dollars. With losses continuing and no positive operating cash flow demonstrated, funding needs and dilution/financing risk remain material.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	1.00M	7.60M
Gross Profit	0.00	0.00	0.00	900.00K	7.40M
EBITDA	-28.27M	632.00K	529.00K	-31.49M	-18.32M
Net Income	-26.86M	-30.88M	-37.34M	-41.30M	-20.70M
Balance Sheet
Total Assets	78.34M	19.43M	6.22M	20.94M	26.43M
Cash, Cash Equivalents and Short-Term Investments	71.89M	13.89M	2.53M	17.13M	21.45M
Total Debt	1.00M	1.00M	906.00K	945.00K	808.00K
Total Liabilities	7.47M	9.97M	14.20M	16.09M	6.08M
Stockholders Equity	70.87M	9.46M	-7.98M	4.85M	20.35M
Cash Flow
Free Cash Flow	-28.39M	-35.40M	-36.91M	-28.31M	-26.02M
Operating Cash Flow	-28.39M	-35.40M	-31.41M	-23.81M	-26.02M
Investing Cash Flow	0.00	0.00	-5.50M	-4.50M	0.00
Financing Cash Flow	86.30M	46.76M	22.32M	24.08M	12.07M

SELLAS Life Sciences Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLS, the sentiment is Positive. The current price of 4.11 is below the 20-day moving average (MA) of 5.17, below the 50-day MA of 4.44, and above the 200-day MA of 2.54, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 48.21 is Neutral, neither overbought nor oversold. The STOCH value of 15.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLS.

SELLAS Life Sciences Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	52 Neutral	$120.88M	6.18	17.46%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SLS	49 Neutral	$854.81M	―	-63.06%	―	―	59.04%
DMAC	49 Neutral	$352.04M	-9.89	-83.21%	―	―	-29.73%
VYGR	47 Neutral	$229.16M	-1.93	-48.94%	―	-80.88%	-388.61%
GALT	46 Neutral	$177.32M	-8.32	32.59%	―	―	18.82%

SELLAS Life Sciences Group Corporate Events

SELLAS Strengthens Capital Base Through Warrant Exercises

SELLAS Life Sciences Group, Inc., a biopharmaceutical developer of cancer therapies, continues to build its capital base through the exercise of outstanding common stock warrants. The company focuses on novel oncology treatments for hematologic cancers and solid tumors, aiming to advance its clinical programs and strengthen its position in the life sciences sector.

Between December 31, 2025 and March 11, 2026, SELLAS raised approximately $42.6 million in gross proceeds from the exercise of common stock warrants, with about $26.5 million received by January 8, 2026 and an additional $16.1 million thereafter. As of March 11, 2026, the company had 179,536,724 shares of common stock outstanding, reflecting the equity issuance tied to these warrant exercises and signaling an enhanced cash position for ongoing operations and development efforts.

The most recent analyst rating on (SLS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SELLAS Life Sciences Group stock, see the SLS Stock Forecast page.

SELLAS Raises $26.5 Million Through Warrant Exercises

Subsequent to December 31, 2025, SELLAS Life Sciences Group, a biopharmaceutical company, received approximately $26.5 million in cash proceeds from the exercise of common stock warrants, strengthening its capital position and potentially extending its operating runway. As of January 7, 2026, the company had 170,282,026 shares of common stock outstanding, reflecting a meaningful increase in share count that may have implications for existing shareholders’ ownership dilution and future capital markets activity.

The most recent analyst rating on (SLS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SELLAS Life Sciences Group stock, see the SLS Stock Forecast page.